The Ally Bridge Group is led by a group of partners who have distinguished backgrounds and complementary experience in private equity, hedge fund, healthcare, finance, operations and management. Mr. Yu is the founder, CEO and CIO of the firm who carries a strong track record as an investment manager across multiple funds and strategies. Previously, Mr. Yu was Managing Director and Head of China Investments at Och-Ziff Capital Management (OZ), a leading global hedge fund, where he made some of OZ’s largest and highly successful investments. Prior to Och-Ziff, Mr. Yu was a Managing Director at Goldman Sachs in Hong Kong, where he headed several business units and played instrumental roles in some of the most important restructuring, IPO and M&A transactions of leading Chinese companies. Mr. Yu also advised leading global institutions on their China and Asia strategies and transactions. Before Goldman Sachs, Mr. Yu worked at Moody’s in New York, and then Credit Suisse in London and Hong Kong.
Since 2010, Mr. Yu has founded, launched and managed 4 funds covering venture, growth, buyout and hedge fund investing from China to U.S. to Europe. Mr. Yu excels in originating and executing major investment themes such as global life science investing, which has become the primary focus of Mr. Yu and Ally Bridge, creating high-impact deals such as the landmark US$3.3 billion WuXi Pharmatech. He has expertise in cementing strategic transactions between emerging players and industry leaders, between companies in China, the U.S. and Europe, and helping global companies to access the China market while assisting Chinese companies to acquire novel technologies overseas.